Perceptive Advisors LLC purchased a new stake in shares of Teleflex Incorporated (NYSE:TFX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 55,200 shares of the medical technology company’s stock, valued at approximately $13,357,000. Perceptive Advisors LLC owned 0.12% of Teleflex as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Asset Management One Co. Ltd. lifted its stake in shares of Teleflex by 20.8% during the third quarter. Asset Management One Co. Ltd. now owns 83,355 shares of the medical technology company’s stock valued at $20,143,000 after acquiring an additional 14,377 shares during the period. AMP Capital Investors Ltd lifted its stake in shares of Teleflex by 75.0% during the third quarter. AMP Capital Investors Ltd now owns 29,171 shares of the medical technology company’s stock valued at $7,058,000 after acquiring an additional 12,498 shares during the period. Nomura Asset Management Co. Ltd. lifted its stake in shares of Teleflex by 4.8% during the third quarter. Nomura Asset Management Co. Ltd. now owns 15,190 shares of the medical technology company’s stock valued at $3,676,000 after acquiring an additional 690 shares during the period. Graticule Asia Macro Advisors LLC acquired a new position in shares of Teleflex during the third quarter valued at $3,049,000. Finally, Invictus RG lifted its stake in shares of Teleflex by 248.7% during the third quarter. Invictus RG now owns 2,120 shares of the medical technology company’s stock valued at $513,000 after acquiring an additional 1,512 shares during the period. 89.31% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Incorporated (NYSE TFX) traded up $1.68 during trading hours on Friday, hitting $252.76. The company had a trading volume of 333,541 shares, compared to its average volume of 263,596. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. The company has a market capitalization of $11,386.58, a P/E ratio of 31.24, a PEG ratio of 2.16 and a beta of 1.09. Teleflex Incorporated has a fifty-two week low of $154.32 and a fifty-two week high of $271.23.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.11. The business had revenue of $534.70 million during the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. Teleflex’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period last year, the company earned $1.80 earnings per share. research analysts anticipate that Teleflex Incorporated will post 8.35 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Wednesday, November 15th will be issued a dividend of $0.34 per share. The ex-dividend date is Tuesday, November 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.54%. Teleflex’s payout ratio is presently 24.82%.

Several equities analysts have recently issued reports on the company. ValuEngine lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Jefferies Group upped their price target on Teleflex from $270.00 to $295.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Morgan Stanley upped their price target on Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Piper Jaffray Companies assumed coverage on Teleflex in a research note on Friday, November 10th. They set an “overweight” rating and a $295.00 price target on the stock. Finally, Deutsche Bank lowered Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price target on the stock. in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company’s stock. Teleflex has an average rating of “Hold” and a consensus target price of $274.44.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $237.18, for a total value of $47,436.00. Following the completion of the transaction, the director now directly owns 8,080 shares in the company, valued at $1,916,414.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Benson Smith sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $258.10, for a total value of $516,200.00. Following the completion of the transaction, the chief executive officer now owns 76,634 shares of the company’s stock, valued at $19,779,235.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,600 shares of company stock valued at $665,076. 2.39% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Perceptive Advisors LLC Invests $13.36 Million in Teleflex Incorporated (TFX)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/10/perceptive-advisors-llc-invests-13-36-million-in-teleflex-incorporated-tfx.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Stock Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related stocks with our FREE daily email newsletter.